Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is ‘cured’ from postoperative recurrence?

Role of surgery in the multimodal treatment of primary and recurrent leiomyosarcoma of the inferior vena cava

(2016) Ferdinando Carlo Maria Cananzi et al.   JOURNAL OF SURGICAL ONCOLOGY

Postoperative oligo-recurrence of non-small-cell lung cancer: clinical features and survival

(2015) Tomoyuki Hishida et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

(2015) Yoshihito Kogure et al.   PLoS One

Prognostic Factors and the Significance of Treatment After Recurrence in Completely Resected Stage I Non-small Cell Lung Cancer

(2013) Yoshihisa Shimada et al.   CHEST

Risk Factors for Tumor Recurrence in Patients With Early-Stage (Stage I and II) Non-small Cell Lung Cancer

(2011) Ryo Maeda et al.   CHEST

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

(2011) Masahiro Fukuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)

(2011) Sumitra Thongprasert et al.   Journal of Thoracic Oncology